Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $21.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst commented: "Yesterday ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments